Other languages AnaptysBio, Inc.

Equities

ANAB

US0327241065

Market Closed - Nasdaq Other stock markets 02:00:00 04/05/2024 am IST			5-day change	1st Jan Change
26.58 ^USD	+0.91%		+26.57%	+24.09%

16/04	Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target	MT
11/04	Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AnaptysBio Shares Jump on Upgrade by Wedbush	12/03
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12/03
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	12/03
AnaptysBio Shares Climb as Piper Sandler Starts Coverage With Overweight Rating	17/02
GSK : l'UE approuve Jemperli dans le cancer de l'endomètre	11/12
AnaptysBio Secures Exclusive License for Centessa's BDCA2 Modulator Antibody Portfolio	28/11
AnaptysBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
AnaptysBio's Phase 3 Trial of Imsidolimab to Treat Generalized Pustular Psoriasis Meets Primary Endpoint	09/23/09
AnaptysBio's skin disease drug meets main goal in late-stage study	09/23/09
AnaptysBio, Inc. Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis	09/23/09
AnaptysBio, Inc. Announces Board Changes	19/23/19
AnaptysBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	08/23/08
AnaptysBio, Inc. and GSK-Partner Immuno-Oncology Agent Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approved in U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer	31/23/31
AnaptysBio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12
AnaptysBio, Inc. Announces Board Changes	07/23/07
AnaptysBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	02/23/02
AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	02/23/02
Sector Update: Health Care Stocks Steady Friday Afternoon While Other Sectors Rebound	14/23/14
Sector Update: Health Care Standing Firm as Broader Markets Catch Up	14/23/14
AnaptysBio Approves $50 Million Share Buyback Plan; Stock Gains	13/23/13

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages AnaptysBio, Inc.

Equities

ANAB

US0327241065

Other languages

Filters